Navigation Links
Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Date:6/19/2012

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.

The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. The stopping criterion was a serious adverse event. It is suspected that the subject may have had an allergic reaction following his first dose. The subject was treated at the clinical site and has fully recovered. A review and investigation of the incident has commenced.

"We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "AstraZeneca has confirmed their remaining commitment to the continued advancement of melanocortin agonists for treatment of obesity, including a number of collaboration compounds in various stages of preclinical testing."

The phase I single center study, conducted by AstraZeneca, targeted enrolling 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m2, in a randomized, single-blind, placebo-controlled, trial. Eleven subjects had completed their dosing regimen prior to the halting of the trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820 after administration of multiple ascending doses. Another Phase 1 single ascending dose study of AZD2820 was finalize
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
2. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
8. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
9. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
10. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
11. Metamaterials, quantum dots show promise for new technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Portal Solutions , a technology consulting firm that designs ... and SharePoint platforms , today announces its inclusion in Washington ... the region’s fastest-growing mid-sized companies based on a combined three-year ... recognized a second year in a row by SmartCEO is ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Approved in Atlanta ATLANTA, May 19 Meeting ... the Kansas Bioscience Authority has approved more than ... a $581 million initiative to help researchers and ... at the Bio International Convention will create bioscience ...
... availability of the world,s first clinical guidelines to allow U.S. doctors ... disease. , ... Broomfield, CO (PRWEB) May 19, 2009 ... today the availability of the world,s first clinical guidelines to allow ...
... illustrate potential cost effective approach for, ... Symbol: RVX,CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - ... pleased to announce today that it has made ... (R&D) program for inflammatory diseases. Two new patent ...
Cached Biology Technology:As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 2As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 3As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 4Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 2Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 3Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 4Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 2Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 3
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... of cancer cells can be switched on using drugs, ... Center. The finding could lead to a new class ... different cancer types. , Popular new drugs such as ... genetic mutations that express themselves in large amounts, causing ...
... the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian ... antibodies in human blood that may help to ... as other neurodegenerative diseases. , The newly ... proteins called "oligomers" that are toxic to brain ...
... the protein complex implicated in autism spectrum disorders, a ... California, San Diego (UCSD) Skaggs School of Pharmacy and ... this complex and contribute to the developmental abnormalities found ... cover article in the June issue of the journal ...
Cached Biology News:U-M researchers discover gene switched off in cancer can be turned on 2U-M researchers discover gene switched off in cancer can be turned on 3Newly discovered antibody may be body's natural defense against Alzheimer's 2Newly discovered antibody may be body's natural defense against Alzheimer's 3Researchers reveal structure of protein altered in autism 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: